Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Conditions: Retinitis Pigmentosa Interventions: Drug: VG901 Sponsors: ViGeneron GmbH Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials